ScholarIQanswers from OpenAlex

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling

PaperCitations, authors & open-access status

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling have?

ScholarIQcitation count

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling has 396 citations in the OpenAlex counts ScholarIQ stores.

When was Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling published?

ScholarIQyear

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling has 2009 year in the ScholarIQ index.

What is the open-access status of Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling?

ScholarIQoa status

Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling has bronze oa status in the ScholarIQ index.

What is the DOI of Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling?

ScholarIQdoi

The DOI for Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling is on the source record.

What is the PMID of Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling?

ScholarIQpmid

The PMID for Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling is on the source record.

What is the OpenAlex record for Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling?

ScholarIQopenalex

The OpenAlex for Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial